Website news release
Latest update on TIES Solution – January 2018
Message from CEO Ostomycure Dr Benedict Broenniman M.D.
In consultation with our Notified Body, it has been decided to collect additional clinical data in a new clinical study at specialized colorectal units in the UK & Sweden. The previous sponsored studies have shown the implant’s short and long-term safety profile. The aim of the new clinical study “TIES-C03” is to evaluate the long-term performance, safety, and impact of the TIES solution on quality of life. The patient´s perspective on the use of the TIES solution for controlled bowel emptying will also be included in the assessment.
“We know that TIES Solution is a safe concept for ileostomy patients What we would like to establish is a scientifical base which will prove our product claims in a small number of clinical centers “says CEO Ostomycure Dr. med. Benedict Broenniman”.
The new study is planned to start in April 2018 with follow-up throughout 2019. The investigators are Associate Professor Karin Strigård and Professor Ulf Gunnarsson in Umeå (Sweden), and Professor David Jayne in Leeds